Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy
International Journal of Clinical Oncology2017Vol. 22(5), pp. 972–979
Citations Over Time
Masayuki Shiseki, Chikashi Yoshida, Naoki Takezako, Akira Ohwada, Takashi Kumagai, Kaichi Nishiwaki, Akira Horikoshi, Tetsuya Fukuda, Hina Takano, Yasuji Kouzai, Junji Tanaka, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi
Abstract
Switching to dasatinib would be a therapeutic option for CP-CML patients who achieved MMR but not DMR by imatinib, especially for patients who wish to discontinue TKI therapy.
Related Papers
- → Acute Renal Failure under Dasatinib Therapy(2010)33 cited
- → Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib(2014)20 cited
- → Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias(2007)37 cited
- → Strategies for overcoming imatinib resistance in chronic myeloid leukemia(2007)29 cited
- → The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia(2016)3 cited